Harmony Biosciences (NASDAQ:HRMY) Raised to “Strong-Buy” at Zacks Research

Posted by Brian Himes on Jul 15th, 2026

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Several other equities analysts also recently commented on the stock. Weiss Ratings raised shares of Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, June 23rd. HC Wainwright reiterated a “buy” rating on shares of Harmony Biosciences in a research note on Wednesday, June 24th. Deutsche Bank Aktiengesellschaft raised their price objective on Harmony Biosciences from $30.00 to $36.00 and gave the company a “hold” rating in a report on Tuesday, June 30th. Finally, Truist Financial upped their target price on Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Harmony Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.50.

Read Our Latest Stock Report on HRMY

Harmony Biosciences Stock Down 2.1%

Shares of NASDAQ HRMY opened at $34.81 on Monday. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.02 billion, a price-to-earnings ratio of 14.04, a PEG ratio of 0.33 and a beta of 0.94. Harmony Biosciences has a 12 month low of $25.52 and a 12 month high of $40.87. The stock has a 50-day moving average price of $33.32 and a two-hundred day moving average price of $32.76.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). The company had revenue of $215.39 million during the quarter, compared to analyst estimates of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The company’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.78 earnings per share. As a group, analysts forecast that Harmony Biosciences will post 3.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Harmony Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in HRMY. SG Americas Securities LLC increased its position in shares of Harmony Biosciences by 109.9% during the first quarter. SG Americas Securities LLC now owns 2,018,174 shares of the company’s stock worth $56,529,000 after buying an additional 1,056,507 shares during the period. Armistice Capital LLC acquired a new position in Harmony Biosciences in the fourth quarter valued at $18,710,000. AQR Capital Management LLC boosted its position in Harmony Biosciences by 128.9% during the fourth quarter. AQR Capital Management LLC now owns 813,889 shares of the company’s stock valued at $30,456,000 after acquiring an additional 458,321 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Harmony Biosciences by 42.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,295,381 shares of the company’s stock worth $35,701,000 after acquiring an additional 388,472 shares during the period. Finally, UBS Group AG grew its holdings in Harmony Biosciences by 213.3% during the 3rd quarter. UBS Group AG now owns 503,081 shares of the company’s stock worth $13,865,000 after acquiring an additional 342,505 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

(Get Free Report)

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.